Kilitch Drugs Limited Stock Fundamentals

KILITCH Stock   307.45  2.60  0.84%   
Kilitch Drugs Limited fundamentals help investors to digest information that contributes to Kilitch Drugs' financial success or failures. It also enables traders to predict the movement of Kilitch Stock. The fundamental analysis module provides a way to measure Kilitch Drugs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kilitch Drugs stock.
As of now, Kilitch Drugs' EBITDA is decreasing as compared to previous years. The Kilitch Drugs' current Cost Of Revenue is estimated to increase to about 969.4 M, while Depreciation And Amortization is projected to decrease to under 32.6 M.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Kilitch Drugs Limited Company Return On Asset Analysis

Kilitch Drugs' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Kilitch Drugs Return On Asset

    
  0.0566  
Most of Kilitch Drugs' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kilitch Drugs Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Kilitch Total Assets

Total Assets

1.67 Billion

As of now, Kilitch Drugs' Total Assets are increasing as compared to previous years.
Based on the latest financial disclosure, Kilitch Drugs Limited has a Return On Asset of 0.0566. This is 100.65% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on asset for all India stocks is 140.43% lower than that of the firm.

Kilitch Drugs Limited Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kilitch Drugs's current stock value. Our valuation model uses many indicators to compare Kilitch Drugs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kilitch Drugs competition to find correlations between indicators driving Kilitch Drugs's intrinsic value. More Info.
Kilitch Drugs Limited is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about  0.68  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Kilitch Drugs Limited is roughly  1.47 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Kilitch Drugs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kilitch Drugs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Kilitch Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kilitch Drugs' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kilitch Drugs could also be used in its relative valuation, which is a method of valuing Kilitch Drugs by comparing valuation metrics of similar companies.
Kilitch Drugs is currently under evaluation in return on asset category among its peers.

Kilitch Fundamentals

About Kilitch Drugs Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kilitch Drugs Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kilitch Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kilitch Drugs Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue53.1 M59.2 M
Total Revenue1.5 B889.7 M
Cost Of Revenue923.2 M969.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Kilitch Stock

Kilitch Drugs financial ratios help investors to determine whether Kilitch Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kilitch with respect to the benefits of owning Kilitch Drugs security.